{"result": {"id": "e4c9fcb9-88da-4f74-bb09-2020f437f113", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>LVH<|>EVENT<|>Left Ventricular Hypertrophy, a condition where ARB is particularly effective for treatment\")  \n##\n(\"entity\"<|>HFpEF<|>EVENT<|>Heart Failure with preserved Ejection Fraction, a condition where ARB is recommended\")  \n##\n(\"entity\"<|>PROTEINURIA<|>EVENT<|>Excessive protein in urine, a condition improved by ARB treatment\")  \n##\n(\"entity\"<|>METABOLIC SYNDROME<|>EVENT<|>A cluster of conditions where ARB is beneficial\")  \n##\n(\"entity\"<|>CKD<|>EVENT<|>Chronic Kidney Disease, where ARB requires careful monitoring of potassium and creatinine\")  \n##\n(\"entity\"<|>HYPERKALEMIA<|>EVENT<|>High blood potassium, a contraindication for ARB and ACEI use\")  \n##\n(\"entity\"<|>BILATERAL RENAL ARTERY STENOSIS<|>EVENT<|>A contraindication for ARB and ACEI use\")  \n##\n(\"entity\"<|>PREGNANCY<|>EVENT<|>A contraindication for ARB, ACEI, and ARNI use\")  \n##\n(\"relationship\"<|>ARB<|>LVH<|>ARB is particularly effective in treating Left Ventricular Hypertrophy<|>8)  \n##\n(\"relationship\"<|>ARB<|>HFpEF<|>ARB is recommended for Heart Failure with preserved Ejection Fraction<|>8)  \n##\n(\"relationship\"<|>ARB<|>PROTEINURIA<|>ARB reduces proteinuria in diabetic and non-diabetic kidney disease<|>9)  \n##\n(\"relationship\"<|>ARB<|>METABOLIC SYNDROME<|>ARB is beneficial for patients with metabolic syndrome<|>7)  \n##\n(\"relationship\"<|>ARB<|>CKD<|>ARB requires monitoring in Chronic Kidney Disease due to risks of hyperkalemia<|>7)  \n##\n(\"relationship\"<|>ARB<|>HYPERKALEMIA<|>Hyperkalemia is a risk when using ARB, especially in CKD patients<|>8)  \n##\n(\"relationship\"<|>ARB<|>BILATERAL RENAL ARTERY STENOSIS<|>ARB is contraindicated in bilateral renal artery stenosis<|>9)  \n##\n(\"relationship\"<|>ARB<|>PREGNANCY<|>ARB is contraindicated in pregnancy due to fetal risks<|>9)  \n##\n(\"relationship\"<|>ACEI<|>HYPERKALEMIA<|>ACEI increases the risk of hyperkalemia, similar to ARB<|>8)  \n##\n(\"relationship\"<|>ACEI<|>BILATERAL RENAL ARTERY STENOSIS<|>ACEI is contraindicated in bilateral renal artery stenosis<|>9)  \n##\n(\"relationship\"<|>ACEI<|>PREGNANCY<|>ACEI is contraindicated in pregnancy due to fetal risks<|>9)  \n##\n(\"relationship\"<|>ARNI<|>PREGNANCY<|>ARNI is contraindicated in pregnancy due to fetal risks<|>9)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558648, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 760, "prompt_tokens": 3089, "total_tokens": 3849, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3008}, "prompt_cache_hit_tokens": 3008, "prompt_cache_miss_tokens": 81}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 谢综合征\t妊娠\n高血钾\n双侧肾动脉重度狭窄\t\nARB\t糖尿病肾病\n蛋白尿/微量白蛋白尿 冠心病\n心力衰竭\n左心室肥厚\n心房颤动预防\n　ACEI引起的咳嗽 代谢综合征\t妊娠\n高血钾\n双侧肾动脉重度狭窄\t\nARNI\t心力衰竭\n　心肌梗死后 左心室肥厚 慢性肾脏病 老年高血压\t妊娠\n高血钾\n　双侧肾动脉重度狭窄 重度肾功能损害\t中度肝功能损害\n\n\n续表 17\n\n分类\t适应证\t禁忌证\n\t\t绝对禁忌证\t相对禁忌证\n噻嗪类利尿剂\t心力衰竭\n老年高血压\n高龄老年高血压\n单纯收缩期高血压\t痛风\t妊娠\n袢利尿剂\t　肾功能不全 心力衰竭\t\t\n盐皮质激素受体拮抗剂\t心力衰竭\n心肌梗死后\t　肾功能衰竭 高血钾\t\nβ受体阻滞剂\t心绞痛\n心肌梗死后\n　快速性心律失常 慢性心力衰竭\t二至三度心脏传导阻滞 哮喘\t慢性阻塞性肺疾病\n周围血管病 糖耐量低减 运动员\nα受体阻滞剂\t前列腺增生 高脂血症\t体位性低血压\t心力衰竭\n注 :CCB为钙通道阻滞药;ACEI为血管紧张素转换酶抑制药;ARB为血管紧张素受体阻滞药;ARNI为血管紧张素受体脑啡肽酶抑制剂。\n\n\n　　　(3) ARB: ARB 的作用机制是阻断血管紧张素  1型(angiotensin type1,AT1) 受体而发挥降压作用。 ARB与 AT1受体结合的程度越紧密 ,阻断 AT1受体  的作用越强[254] 。循环中增高的 AngⅡ对未被阻断的血  管紧张素 2 型(angiotensin type2, AT2) 受体起激动  作用 ,可能产生对心血管有利影响 ,包括扩张血管、抗  组织增生等 。ARB具有良好的耐受性而使用广泛。\n　　　ARB能有效地减少高血压患者的主要心血管事  件和死亡率[251,255] 。ARB和 ACEI均可预防新发的糖  尿病和心房颤动[255] ; 比其他降压药更能减少蛋白尿 ,  并能效延缓糖尿病肾病的进展[133] 。ARB尤其适用于  伴 LVH、HFpEF、冠心病、心肌梗死后、心功能不全、 糖尿病肾病、蛋白尿、代谢综合征以及不能耐受 ACEI 的患者[256] 。\n　　　ARB不应与 ACEI或直接肾素抑制剂联合使用 , 因为不能获得额外的益处 ,并导致过多的肾脏事件和 高钾血症[256-257] 。CKD患者长期应用 ARB应定期监 测血钾和血肌酐水平 ,双\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB (Angiotensin Receptor Blocker) is a type of medication that blocks the AT1 receptor to lower blood pressure and is used in treating conditions like hypertension, heart failure, and diabetes nephropathy)\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI (Angiotensin-Converting Enzyme Inhibitor) is a medication used to treat hypertension and heart failure by inhibiting the conversion of angiotensin I to angiotensin II)\n##\n(\"entity\"<|>ARNI<|>ORGANIZATION<|>ARNI (Angiotensin Receptor Neprilysin Inhibitor) is a medication used for heart failure and post-myocardial infarction, combining ARB and neprilysin inhibition)\n##\n(\"entity\"<|>AT1 RECEPTOR<|>ORGANIZATION<|>The AT1 receptor is a target of ARB medications, and blocking it helps in lowering blood pressure and managing cardiovascular conditions)\n##\n(\"entity\"<|>AT2 RECEPTOR<|>ORGANIZATION<|>The AT2 receptor is another angiotensin receptor that may have beneficial cardiovascular effects when activated by Angiotensin II)\n##\n(\"entity\"<|>DIABETES NEPHROPATHY<|>EVENT<|>A condition where ARB and ACEI medications are used to reduce proteinuria and slow disease progression)\n##\n(\"entity\"<|>HEART FAILURE<|>EVENT<|>A condition treated by ARB, ACEI, and ARNI medications to improve outcomes and reduce mortality)\n##\n(\"entity\"<|>MYOCARDIAL INFARCTION<|>EVENT<|>Post-myocardial infarction is a condition where ARNI and other medications are used for management)\n##\n(\"relationship\"<|>ARB<|>AT1 RECEPTOR<|>ARB blocks the AT1 receptor to exert its antihypertensive effects<|>9)\n##\n(\"relationship\"<|>ARB<|>DIABETES NEPHROPATHY<|>ARB is used to reduce proteinuria and slow the progression of diabetes nephropathy<|>8)\n##\n(\"relationship\"<|>ARB<|>HEART FAILURE<|>ARB is used in the treatment of heart failure to improve outcomes<|>8)\n##\n(\"relationship\"<|>ACEI<|>HEART FAILURE<|>ACEI is used in the treatment of heart failure to improve outcomes<|>8)\n##\n(\"relationship\"<|>ARNI<|>HEART FAILURE<|>ARNI is used in the treatment of heart failure and post-myocardial infarction<|>9)\n##\n(\"relationship\"<|>ARB<|>ACEI<|>ARB and ACEI should not be used together due to increased risk of adverse effects<|>7)\n##\n(\"relationship\"<|>ARB<|>AT2 RECEPTOR<|>ARB indirectly allows Angiotensin II to activate AT2 receptors, which may have beneficial effects<|>6)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_b488646ef1af451d59bb6e9eb6e283c006f85db5397c3b394f1db3fc4516629b_v2"}